Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 629pembrolizumab 559Magnetic Resonance Spectroscopy 539Carboplatin 423Cyclophosphamide 371Cisplatin 371Biopsy 357Paclitaxel 304Nivolumab 301Gemcitabine 299Radiotherapy 270Bevacizumab 238Dexamethasone 207fludarabine 205Docetaxel 189durvalumab 178atezolizumab 176Oxaliplatin 172Fluorouracil 167venetoclax 164Rituximab 164Pemetrexed 162Radiation 159Doxorubicin 159Capecitabine 158Radiosurgery 147Etoposide 137Ipilimumab 134Leucovorin 133Lenalidomide 130

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
gevokizumab × 90 days × Clear all
NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Novartis

Phase 1 Completed
167 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡